Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

Stock Information for Design Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.